Our Pricing

Wegovy UK In Stock Now - Best Prices From £69.00

Published on: June 03, 2026

Finding wegovy uk in stock online pharmacy options with transparent pricing can be challenging during ongoing supply fluctuations. At Cured Pharmacy, we maintain reliable Wegovy stock with upfront pricing from £79.00, free clinical consultation under 3 minutes, and discreet next-day delivery across the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the naturally occurring hormone GLP-1, which regulates appetite by acting on areas of the brain that control hunger and food intake.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing appetite, and improving glycaemic control, helping patients feel fuller for longer periods between meals.

Wegovy is administered as a once-weekly subcutaneous injection, starting at a low dose of 0.25mg and gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg. This dose escalation schedule, developed through extensive clinical trials, minimises gastrointestinal side effects whilst optimising therapeutic benefits [2].

Wegovy Dosing Schedule and Administration

The Wegovy treatment programme follows a structured dose escalation protocol designed to improve tolerability. Patients begin with 0.25mg weekly for four weeks, then progress through 0.5mg, 1mg, and 1.7mg doses, each maintained for four weeks, before reaching the maintenance dose of 2.4mg [2].

Each pre-filled pen is designed for single use and should be injected subcutaneously into the abdomen, thigh, or upper arm. Injection sites should be rotated weekly to reduce the risk of lipodystrophy. The medication can be administered at any time of day, with or without meals, but maintaining a consistent weekly schedule optimises treatment adherence.

What to Expect During Dose Escalation

The gradual dose increase allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Most patients experience the greatest appetite suppression within 4-5 weeks of reaching their maintenance dose. During escalation, mild nausea is common but typically resolves as your body adjusts to each new dose level [2].

Wegovy UK Stock Availability and Pricing

Following intermittent supply challenges across UK pharmacies throughout 2023 and early 2024, Wegovy availability has stabilised significantly. At Cured Pharmacy, we maintain consistent stock levels across all dose strengths, with transparent upfront pricing from £79.00 before you complete your clinical consultation.

Unlike some pharmacy models that require consultation before revealing costs, we believe in complete price transparency. Your final cost depends on your prescribed dose strength, which a UK-registered prescriber determines based on your medical history, current medications, and treatment goals. All Wegovy pens dispensed by Cured Pharmacy are genuine UK-licensed products sourced through authorised pharmaceutical wholesalers.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), personally oversees our supply chain and quality assurance processes. Every prescription is clinically reviewed before dispensing, ensuring appropriate prescribing in line with MHRA licensing criteria and NICE guidance on obesity management [3].

Transparent Pricing Before Consultation

We display all treatment costs upfront because we believe patients deserve to make informed decisions before investing time in a clinical assessment. Our pricing includes the medication, prescriber consultation, and discreet home delivery. There are no hidden fees or surprise charges at checkout.

Clinical Eligibility for Wegovy in the UK

Wegovy is licensed for adults with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity.

During your free online consultation at Cured Pharmacy, a UK-registered prescriber will assess your medical history, current medications, and weight management goals. Certain conditions may preclude Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease.

NICE guidance recommends considering GLP-1 receptor agonists like Wegovy for patients who have not achieved adequate weight loss through lifestyle interventions alone [3]. Your prescriber will discuss realistic expectations, potential side effects, and the importance of combining medication with sustainable dietary and activity modifications.

Common Side Effects and Management Strategies

The most frequently reported side effects of Wegovy are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal pain. In clinical trials, these effects were generally mild to moderate in severity and decreased over time as patients adapted to treatment [1][2].

Nausea affects approximately 44% of patients during dose escalation but typically improves within 4-8 weeks. Practical management strategies include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on an empty stomach if nausea is problematic after meals.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concomitant diabetes medications). Patients should seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of pancreatitis. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, and you can contact us on (+44) 116 4646009 with any concerns.

When to Contact Your Prescriber

Contact your prescriber immediately if you experience severe or persistent abdominal pain, changes in vision, signs of thyroid tumours (lump in neck, hoarseness, difficulty swallowing), or symptoms of pancreatitis. Regular follow-up assessments help monitor your progress and adjust treatment as needed.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms of action and clinical profiles. Semaglutide-based treatments like Wegovy offer once-weekly convenience and robust clinical trial data demonstrating superior weight loss compared to older options.

Liraglutide-based treatments require daily injections and typically produce more modest weight loss (average 5-8% body weight) compared to Wegovy's 14.9% average reduction [1][4]. Oral medications like orlistat work through fat malabsorption rather than appetite regulation, often producing 5-10% weight loss but with significant gastrointestinal side effects when dietary fat intake is high.

Tirzepatide represents the newest class of weight loss medication, combining GLP-1 and GIP receptor agonism. Clinical trials suggest even greater weight loss potential than semaglutide, though individual response varies considerably [5]. Your prescriber will recommend the most appropriate option based on your medical history, treatment preferences, and clinical goals.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m² or ≥27 kg/m² in the presence of at least one weight-related comorbidity.